Department of Infectious Diseases, University of Turin, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Turin, Italy.
Int J Infect Dis. 2011 Jun;15(6):e415-21. doi: 10.1016/j.ijid.2011.03.003. Epub 2011 Apr 15.
A main determinant of clinical response to antibiotic treatment is drug concentration at the infected site. Data on ceftriaxone (CFX) bone penetration are lacking. We measured CFX concentrations in infected bone to verify their relationship with pharmacodynamic microbiological markers.
Eleven patients undergoing debridement for septic non-union of the tibia and receiving intravenous CFX were studied. Plasma and bone specimens were collected intraoperatively at a variable interval after CFX administration. Drug concentrations were measured by high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method.
Bone samples were extracted at a mean of 3.3 h (range 1.5-8.0 h) since the start of CFX infusion. The mean±standard deviation intraoperative CFX plasma concentration was 128.4±30.8 mg/l; the corresponding bone concentrations were 9.6±3.4 mg/l (7.8%) in the cortical compartment and 30.8±8.6 mg/l (24.3%) in the cancellous compartment. The mean 24-h area under the concentration-time curve (AUC(24)) values were 176.8±62.2 hmg/l in cortical bone and 461.5±106.8 hmg/l in cancellous bone. The time above the minimum inhibitory concentration (T>MIC) was 24 h in all compartments. The estimated mean free AUC/MIC ratios and T>MIC were 140 and 24.4 h, respectively, in cancellous bone and 42.4 and 21 h, respectively, in cortical bone.
CFX bone penetration was poor (<15%) in the cortical compartment and satisfactory in the more vascularized cancellous bone. The T>MIC and AUC/MIC ratios suggest that CFX achieves a satisfactory pharmacokinetic exposure in cancellous bone as far as pathogens with a MIC of <0.5 are concerned. However, considering free drug concentrations, pharmacokinetic/pharmacodynamic targets may not be fully achieved in cortical bone. As antibiotic exposure can be suboptimal in the infected cortical compartment, and drug penetration may be impaired into necrotic bone and sequesters, a radical surgical removal of purulent and necrotic tissues appears essential to shorten treatment duration and to prevent treatment failures.
临床对抗生素治疗反应的主要决定因素是感染部位的药物浓度。有关头孢曲松(CFX)骨穿透的数据尚缺乏。我们测量了感染骨中的 CFX 浓度,以验证其与药效微生物学标志物的关系。
研究了 11 例因胫骨感染性不愈合而行清创术并接受静脉注射 CFX 的患者。在 CFX 给药后,以可变的时间间隔在术中采集血浆和骨标本。药物浓度通过高效液相色谱法(HPLC-UV)与紫外检测(UV)方法进行测量。
骨样本平均在 CFX 输注开始后 3.3 小时(范围 1.5-8.0 小时)提取。术中 CFX 血浆浓度的平均值±标准差为 128.4±30.8mg/L;皮质骨中相应的骨浓度为 9.6±3.4mg/L(7.8%),松质骨中为 30.8±8.6mg/L(24.3%)。皮质骨的 24 小时 AUC(24)平均值为 176.8±62.2hmg/L,松质骨为 461.5±106.8hmg/L。所有部位的 T>MIC 均为 24 小时。估计的游离 AUC/MIC 比值和 T>MIC 分别为 140 和 24.4h,在松质骨中;42.4 和 21h,在皮质骨中。
CFX 骨穿透性差(<15%),在皮质骨中,在更具血管化的松质骨中令人满意。T>MIC 和 AUC/MIC 比值表明,对于 MIC<0.5 的病原体,CFX 在松质骨中达到了令人满意的药代动力学暴露。然而,考虑到游离药物浓度,皮质骨中可能无法完全达到药代动力学/药效学目标。由于感染的皮质骨中抗生素暴露可能不足,且药物穿透可能受损进入坏死骨和隔离区,因此彻底切除化脓性和坏死性组织似乎对于缩短治疗时间和防止治疗失败至关重要。